---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-264714"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:01:54.846707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS

## Summary
- 50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).
- Biopsy confirmed gamma-delta T cell persistence in brain tumor microenvironment in two patients post-treatment.
- Median PFS in repeat-dose patients increased 79% vs. 6.9 months for Stupp regimen.
- No treatment-related serious adverse events, cytokine release syndrome, or neurotoxicity reported.
- One IDH-mutant glioma patient remains alive and progression-free at 40.5 months.

## SEC filing metadata
- accession: 0001193125-24-264714
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/0001193125-24-264714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/d844601d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-264714
- JSON: https://secwatch.observer/filing/0001193125-24-264714.json
- Plain text: https://secwatch.observer/filing/0001193125-24-264714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.